ALLIANCEBERNSTEIN L.P. - SAREPTA THERAPEUTICS INC ownership

SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 353 filers reported holding SAREPTA THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.81 and the average weighting 0.2%.

Quarter-by-quarter ownership
ALLIANCEBERNSTEIN L.P. ownership history of SAREPTA THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$33,870,618
-17.8%
214,371
-32.6%
0.01%
-20.0%
Q1 2024$41,198,962
+66.9%
318,237
+24.4%
0.02%
+66.7%
Q4 2023$24,677,498
-57.0%
255,911
-46.0%
0.01%
-62.5%
Q3 2023$57,416,095
+0.0%
473,652
-5.5%
0.02%
+4.3%
Q2 2023$57,408,991
-15.0%
501,301
+2.3%
0.02%
-20.7%
Q1 2023$67,568,677
+379.7%
490,232
+351.0%
0.03%
+383.3%
Q4 2022$14,086,383
-8.7%
108,708
-22.1%
0.01%
-14.3%
Q3 2022$15,432,000
-6.5%
139,609
-36.6%
0.01%
-12.5%
Q2 2022$16,497,000
-17.2%
220,076
-13.7%
0.01%0.0%
Q1 2022$19,926,000
+109.9%
255,064
+141.9%
0.01%
+166.7%
Q4 2021$9,494,000
-26.6%
105,433
-24.6%
0.00%
-40.0%
Q3 2021$12,935,000
+327.5%
139,863
+259.3%
0.01%
+400.0%
Q2 2021$3,026,000
-16.2%
38,928
-19.7%
0.00%
-50.0%
Q1 2021$3,612,000
-95.8%
48,465
-90.3%
0.00%
-95.0%
Q4 2020$85,138,000
+31.2%
499,371
+8.1%
0.04%
+14.3%
Q3 2020$64,901,000
-21.3%
462,159
-10.1%
0.04%
-27.1%
Q2 2020$82,456,000
+80.4%
514,259
+10.1%
0.05%
+45.5%
Q1 2020$45,704,000
-22.3%
467,228
+2.5%
0.03%0.0%
Q4 2019$58,795,000
+45.2%
455,636
-15.2%
0.03%
+32.0%
Q3 2019$40,490,000
-46.1%
537,574
+8.7%
0.02%
-46.8%
Q2 2019$75,159,000
+9.8%
494,628
-13.9%
0.05%
+4.4%
Q1 2019$68,467,000
+5.4%
574,435
-3.5%
0.04%
-6.2%
Q4 2018$64,937,000
+48.4%
595,041
+119.6%
0.05%
+65.5%
Q3 2018$43,755,000
-16.8%
270,911
-31.9%
0.03%
-21.6%
Q2 2018$52,562,000
+271.0%
397,655
+108.0%
0.04%
+270.0%
Q1 2018$14,166,000
+117.0%
191,200
+62.9%
0.01%
+100.0%
Q4 2017$6,529,000
-15.4%
117,340
-31.0%
0.01%
-16.7%
Q3 2017$7,718,000
+93.5%
170,140
+43.8%
0.01%
+100.0%
Q2 2017$3,988,000
+85.9%
118,310
+63.3%
0.00%
+50.0%
Q1 2017$2,145,000
+8.0%
72,4500.0%0.00%0.0%
Q4 2016$1,987,000
-48.4%
72,450
+15.5%
0.00%
-33.3%
Q3 2016$3,853,000
+118.3%
62,750
-32.2%
0.00%
+50.0%
Q2 2016$1,765,000
+30.9%
92,550
+34.0%
0.00%
+100.0%
Q1 2016$1,348,000
-49.4%
69,0500.0%0.00%
-50.0%
Q4 2015$2,664,000
+19.1%
69,050
-0.9%
0.00%0.0%
Q3 2015$2,236,000
+6.6%
69,650
+1.1%
0.00%0.0%
Q2 2015$2,097,000
+162.5%
68,900
+14.5%
0.00%
+100.0%
Q1 2015$799,000
-18.0%
60,200
-10.5%
0.00%0.0%
Q4 2014$974,000
-31.4%
67,3000.0%0.00%0.0%
Q3 2014$1,420,000
-29.2%
67,3000.0%0.00%
-50.0%
Q2 2014$2,005,000
+24.0%
67,3000.0%0.00%
+100.0%
Q1 2014$1,617,000
+17.9%
67,3000.0%0.00%0.0%
Q4 2013$1,371,000
-56.9%
67,3000.0%0.00%
-66.7%
Q3 2013$3,179,000
-70.1%
67,300
-75.9%
0.00%
-72.7%
Q2 2013$10,646,000279,8020.01%
Other shareholders
SAREPTA THERAPEUTICS INC shareholders Q3 2018
NameSharesValueWeighting ↓
Casdin Capital, LLC 1,073,500$169,613,00013.00%
Ally Bridge Group (NY) LLC 73,500$11,613,0006.92%
EcoR1 Capital, LLC 1,407,322$222,356,8766.80%
Logos Global Management LP 500,000$79,000,0006.41%
Avoro Capital Advisors LLC 3,000,000$474,000,0006.31%
Finepoint Capital LP 132,835$20,987,9305.96%
Paradigm Biocapital Advisors LP 947,574$149,716,6925.73%
Ikarian Capital, LLC 203,612$32,170,6965.60%
Boxer Capital, LLC 650,000$102,700,0005.41%
Altium Capital Management LP 81,900$12,940,2005.28%
View complete list of SAREPTA THERAPEUTICS INC shareholders